PACIRA BIOSCIENCES INC (PCRX)
Health Care · Non-opioid pain management biopharmaceuticals · NASDAQ
Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain.
What PACIRA BIOSCIENCES INC does
Pacira BioSciences develops and commercializes non-opioid pain management therapies. The company operates three approved products: EXPAREL (long-acting bupivacaine injectable for postsurgical pain), ZILRETTA (extended-release corticosteroid injection for osteoarthritis knee pain), and iovera° (handheld device delivering cryotherapy for nerve pain relief). The company also advances a clinical-stage gene therapy pipeline including PCRX-201, a locally administered gene therapy for osteoarthritis of the knee.
Themes: ["Non-opioid pain management","Postsurgical pain","Osteoarthritis treatment","Gene therapy / HCAd platform","Local anesthetics"]
Fundamentals
- Price$25.50 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return+10.1% as of 2026-07-09 close
- P/E195.49 as of 2026-07-10
- Net margin+0.7% as of 2026-07-10
- Gross margin+79.3% as of 2026-07-10
- ROE+0.7% as of 2026-07-10
- Debt / equity0.56 as of 2026-07-10
- Revenue growth (YoY)+4.6% as of 2026-07-10
- Revenue CAGR (3y)+2.9% SEC XBRL
- Beta0.26 as of 2026-07-10
Key risks (from latest filing)
["Continued dependence on three primary commercial products (EXPAREL, ZILRETTA, iovera°) for revenue generation, with limited near-term product diversification","Clinical development risk on PCRX-201 gene therapy and other pipeline programs; failure to advance or obtain regulatory approval could impact long-term growth","Competitive pressure from opioid and non-opioid pain management alternatives from larger pharmaceutical competitors"]
Competitors & peers
- Astellas (local anesthetics)
- Assertio Therapeutics
- Naurex (pain management)
- Revance Therapeutics (neurotoxin / esthetic injectables)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.